


Aurora B Control Slides



Intended Use

For In Vitro Diagnostic Use.

Summary and Explanation

Aurora B kinase, a 39.3 kDa sized serine-threonine kinase, is a member of the Aurora family of mitotic kinases. The enzymatic activity of Aurora B kinase prevents stable kinetochore-microtubule attachments in early mitosis and promotes stabilization of the attachments in later mitosis due to low activity. The gene for Aurora B kinase is located on chromosome 17p13.1.

Abnormal expression of Aurora B kinase has been found in many cancer types, such as Non-Small Cell Lung Carcinoma, Mesothelioma, Glioblastoma, Oral Cancer and Hepatocellular Carcinoma. In Prostate and Colorectal Cancer, Aurora B expression directly correlates with the progression of cancer. In a study investigating the expression of Aurora B kinase in Thyroid Carcinoma, abundant expression of Aurora B kinase was detected in Anaplastic Carcinomas via IHC. A higher expression of Aurora B kinase in Anaplastic Thyroid Cancer than in differentiated Thyroid Cancer therefore suggests its use as a prognostic marker. In another immunohistochemical analysis, Aurora B kinase showed nuclear overexpression in high Gleason-grade Prostate Cancer, compared to low and intermediate grade cases. Additionally, there are numerous studies that indicate the use of Aurora B kinase as a prognostic marker in Ovarian Cancer. A study found that Aurora-B expression was correlated with the proliferation index ($P < 0.001$) and p53 expression ($P = 0.014$) in Breast cancer tissues and its expression was associated with lymph node metastasis ($P = 0.002$) and histological grade ($P = 0.001$). In conclusion, elevated Aurora-B expression in Breast Cancer patients contributes to chemoresistance and predicts poor prognosis.

Presentation

Five slides of Aurora B positive tissues, each mounted on Hydrophilic Plus Slides, provided in a plastic mailer.

Catalog No.	Quantity
BSB-9023-CS	5 slides
BSB-3712-CS	5 slides

Storage Store at 20-25°C

Precautions

1. For professional users only. Results should be interpreted by a qualified medical professional.
2. Ensure proper handling procedures are used with this reagent.
3. Always wear personal protective equipment such as a laboratory coat, goggles, and gloves when handling reagents.
4. Dispose of unused solution with copious amounts of water.
5. Follow safety precautions of the heating device used for epitope retrieval (TintoRetriever Pressure Cooker or similar).
8. For additional safety information, refer to Safety Data Sheet for this product.
9. For complete recommendations for handling biological specimens, please refer to the CDC document, "Guidelines for Safe Work Practices in Human and Animal Medical Diagnostic Laboratories" (see References in this document).

Stability

This product is stable up to the expiration date on the product label.
Do not use after expiration date listed on package label.

IHC Protocol

1. Subject tissues to heat induced epitope retrieval (HIER) using a suitable retrieval solution such as ImmunoDNA Retriever with Citrate (BSB 0020-BSB 0023) or EDTA (BSB 0030-BSB 0033).

2. Any of three heating methods may be used:

a. TintoRetriever Pressure Cooker or Equivalent

Place tissues/slides in a staining dish or coplin jar containing the ImmunoDNA Retriever with Citrate or EDTA and place on trivet in the pressure cooker. Add 1-2 inches of distilled water to the pressure cooker and turn heat to high. Incubate for 15 minutes. Open and immediately transfer slides to room temperature.

b. TintoRetriever PT Module or Water Bath Method

Place tissues/slides in a pre-warmed staining dish or coplin jar containing the ImmunoDNA Retriever with Citrate or EDTA at 95°-99° C. Incubate for 30-60 minutes.

c. Conventional Steamer Method

Place tissues/slides in a pre-warmed staining dish or coplin jar containing the ImmunoDNA Retriever with Citrate or EDTA in a steamer, cover and steam for 30-60 minutes.

3. After heat treatment, transfer slides in ImmunoDNA Retriever with Citrate or EDTA to room temperature and let stand for 15-20 minutes.
4. For manual staining, perform antibody incubation at ambient temperature. For automated staining methods, perform antibody incubation according to instrument manufacturer's instructions.
5. Wash slides with ImmunoDNA washer or DI water.
6. Continue IHC staining protocol. Wash slides between each step with ImmunoDNA washer solution.

Abbreviated Immunohistochemical Protocol

Step	ImmunoDetector AP/HRP	PolyDetector AP/HRP	PolyDetector Plus HRP
Peroxidase/AP Blocker	5 min.	5 min.	5 min
Primary Antibody	30-60 min.	30-60 min.	30-60 min.
1st Step Detection	10 min.	30-45 min.	15 min.
2nd Step Detection	10 min.	Not Applicable	15 min.
Substrate- Chromogen	5-10 min.	5-10 min.	5-10 min.
Counterstain / Coverslip	Varies	Varies	Varies

Abbreviated IF Protocol

Step	Incubation Time
Rinse slides in IF wash buffer	5 minutes
Drain and wipe excess IF wash buffer off slide	
Conduct remaining steps in the dark	
Apply Antibody	30-60 minutes
Rinse with 3 changes of IF wash buffer	3x15 minutes each
Coverslip with IF mounting medium	

Mounting Protocols

For detailed instructions using biodegradable permanent mounting media such as XyGreen PermaMunter (BSB 0169-0174) or organic solvent based resin such as PermaMunter (BSB 0094-0097), refer to PI0174 or PI0097.

Product Limitations

Due to inherent variability present in immunohistochemical procedures (including fixation time of tissues, dilution factor of antibody, retrieval method utilized, and incubation time), optimal performance should be established through the use of positive and negative controls. Results should be interpreted by a qualified medical professional.

References

1. Broad AJ, DeLuca KF, DeLuca JG. Aurora B kinase is recruited to multiple discrete kinetochore and centromere regions in human cells. *J Cell Biol.* 2020;219(3):e201905144. doi:10.1083/jcb.201905144
2. Aurora kinase B. <https://www.uniprot.org/uniprot/Q96GD4>
3. Sorrentino R, Libertini S, Pallante PL, et al. Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. *J Clin Endocrinol Metab.* 2005;90(2):928-935. doi:10.1210/jc.2004-1518
4. Chieffi P. Aurora B: A new promising therapeutic target in cancer. *Intractable Rare Dis Res.* 2018;7(2):141-144. doi:10.5582/irdr.2018.01018
5. Chieffi P, Cozzolino L, Kisslinger A, et al. Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation. *Prostate.* 2006;66(3):326-333. doi:10.1002/pros.20345
6. Pérez-Fidalgo JA, Gambardella V, Pineda B, Burgues O, Piñero O, Cervantes A. Aurora kinases in ovarian cancer. *ESMO Open.* 2020;5(5):e000718. doi:10.1136/esmoopen-2020-000718
7. Zhang Y, Jiang C, Li H, et al. Elevated Aurora B expression contributes to chemoresistance and poor prognosis in breast cancer. *Int J Clin Exp Pathol.* 2015;8(1):751-757. Published 2015 Jan 1.
8. U.S. Department of Health and Human Services: Centers for Disease Control and Prevention. Guidelines for Safe Work Practices in Human and Animal Medical Diagnostic Laboratories. Supplement / Vol. 61, January 6, 2012. <https://www.cdc.gov/mmwr/pdf/other/su6101.pdf>

Symbol Key / Légende des symboles/Erläuterung der Symbole

EC REP	QAdvis EAR AB Ideon Science Park Scheelevägen 17 SE-223 70 Lund, Sweden	 Storage Temperature Limites de température Zulässiger Temperaturbereich	 Manufacturer Fabricant Hersteller	REF	Catalog Number Référence du catalogue Bestellnummer
IVD	In Vitro Diagnostic Medical Device Dispositif médical de diagnostic in vitro In-Vitro-Diagnostikum	 Read Instructions for Use Consulter les instructions d'utilisation Gebrauchsanweisung beachten	 Expiration Date Utiliser jusque Verwendbar bis	LOT	Lot Number Code du lot Chargenbezeichnung